Total Payments
$15,206
2024 Payments
$5,593
Companies
19
Transactions
263
Medicare Patients
1,602
Medicare Billing
$609,347
Payment Breakdown by Category
Food & Beverage$5,804 (38.2%)
Other$5,150 (33.9%)
Consulting$2,100 (13.8%)
Travel$2,018 (13.3%)
Education$134.65 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,804 | 249 | 38.2% |
| Honoraria | $2,750 | 1 | 18.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,400 | 1 | 15.8% |
| Consulting Fee | $2,100 | 1 | 13.8% |
| Travel and Lodging | $2,018 | 6 | 13.3% |
| Education | $134.65 | 5 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fresenius USA Marketing, Inc. | $8,902 | 47 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $2,713 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $929.97 | 32 | $0 (2024) |
| Relypsa, Inc. | $731.73 | 104 | $0 (2019) |
| Vifor Pharma, Inc. | $565.37 | 26 | $0 (2024) |
| Amgen Inc. | $314.85 | 6 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $215.83 | 2 | $0 (2019) |
| Travere Therapeutics, Inc. | $154.14 | 9 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $129.58 | 1 | $0 (2019) |
| CALLIDITAS THERAPEUTICS US INC. | $111.39 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,593 | 45 | Fresenius USA Marketing, Inc. ($4,622) |
| 2023 | $3,003 | 33 | Bayer Healthcare Pharmaceuticals Inc. ($2,312) |
| 2022 | $1,208 | 42 | Vifor Pharma, Inc. ($375.03) |
| 2021 | $318.26 | 19 | Fresenius USA Marketing, Inc. ($176.66) |
| 2020 | $107.04 | 1 | Bard Peripheral Vascular, Inc. ($107.04) |
| 2019 | $727.64 | 59 | Relypsa, Inc. ($358.82) |
| 2018 | $228.35 | 26 | Relypsa, Inc. ($188.22) |
| 2017 | $4,022 | 38 | Fresenius USA Marketing, Inc. ($3,739) |
All Payment Transactions
263 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Diabetes | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: Cardio-renal | ||||||
| 11/18/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Nephrology | ||||||
| 11/08/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Cardio-renal | ||||||
| 10/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Cardio-renal | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $32.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $97.23 | General |
| Category: Nephrology | ||||||
| 09/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/30/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: Nephrology | ||||||
| 08/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $30.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/23/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug), FARXIGA | Food and Beverage | In-kind items and services | $35.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/09/2024 | Fresenius USA Marketing, Inc. | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,400.00 | General |
| 08/09/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $525.88 | General |
| 08/09/2024 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $237.36 | General |
| 08/09/2024 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $110.29 | General |
| 08/08/2024 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,235.87 | General |
| 07/29/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Nephrology | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/19/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/14/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $29.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 435 | 1,071 | $330,222 | $185,855 |
| 2022 | 6 | 401 | 1,042 | $315,981 | $176,749 |
| 2021 | 5 | 391 | 965 | $292,537 | $170,162 |
| 2020 | 6 | 375 | 661 | $140,121 | $76,580 |
Total Patients
1,602
Total Services
3,739
Medicare Billing
$609,347
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 31 | 267 | $160,200 | $83,348 | 52.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 232 | 515 | $90,065 | $59,249 | 65.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 56 | 157 | $26,691 | $16,751 | 62.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $28,800 | $14,361 | 49.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 13 | 26 | $13,000 | $6,861 | 52.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 34 | $11,466 | $5,285 | 46.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 29 | 258 | $154,800 | $81,378 | 52.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 230 | 560 | $98,000 | $62,260 | 63.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 56 | 56 | $22,400 | $11,211 | 50.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 48 | 117 | $19,306 | $10,562 | 54.7% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 16 | 28 | $14,000 | $7,286 | 52.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 23 | $7,475 | $4,052 | 54.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 34 | 264 | $150,600 | $84,933 | 56.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 225 | 493 | $86,275 | $56,759 | 65.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 73 | 73 | $29,200 | $14,185 | 48.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 114 | $19,429 | $10,527 | 54.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 21 | $7,033 | $3,759 | 53.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 199 | 423 | $74,025 | $41,823 | 56.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 70 | 70 | $28,000 | $12,784 | 45.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 47 | 107 | $18,172 | $10,140 | 55.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 29 | 29 | $10,049 | $5,372 | 53.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 18 | 19 | $7,600 | $5,094 | 67.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 13 | $2,275 | $1,367 | 60.1% |
About Dr. Randolph Chen, MD
Dr. Randolph Chen, MD is a Nephrology healthcare provider based in Belmont, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962502872.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Randolph Chen, MD has received a total of $15,206 in payments from pharmaceutical and medical device companies, with $5,593 received in 2024. These payments were reported across 263 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($5,804).
As a Medicare-enrolled provider, Chen has provided services to 1,602 Medicare beneficiaries, totaling 3,739 services with total Medicare billing of $609,347. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Belmont, CA
- Active Since 09/22/2006
- Last Updated 05/16/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1962502872
Products in Payments
- Velphoro (Drug) $4,393
- Kerendia (Drug) $2,713
- Veltassa (Drug) $1,160
- LOKELMA (Drug) $485.70
- FARXIGA (Drug) $444.27
- JYNARQUE (Drug) $215.83
- Aranesp (Biological) $162.20
- AURYXIA (Drug) $129.58
- TAVNEOS (Drug) $127.90
- TARPEYO (Drug) $111.39
- KRYSTEXXA (Biological) $69.65
- IBSRELA (Drug) $51.29
- JANUVIA (Drug) $49.13
- EPOGEN (Biological) $24.75
- MOUNJARO (Drug) $24.37
- Mitigare (Drug) $23.41
- SHINGRIX (Drug) $22.50
- LUPKYNIS (Drug) $21.87
- ADVAIR (Drug) $21.32
- JARDIANCE (Drug) $17.73
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.